Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched AnalysisFrancesco Del Giudice, Gian Maria Busetto, Benjamin Pradère et al.|Cancers|2022Cited by 17
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?Gian Maria Busetto, Luigi Cormio, Marco Finati et al.|World Journal of Urology|2023Cited by 7